Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Model and Measurements of an Optical Stack for Broadband Visible to Near-Infrared Absorption in TiN MKIDs.

Journal of low temperature physics·2022
Same author

Structure based designing of thiazolidinone-pyrimidine derivatives as ERK2 inhibitors: Synthesis and in vitro evaluation.

SAR and QSAR in environmental research·2021
Same author

Rhabdomyolysis with myoglobin-induced acute kidney injury: A case series of four cases.

Indian journal of pathology & microbiology·2021
Same author

Bio-process performance, evaluation of enzyme and non-enzyme mediated composting of vegetable market complex waste.

Scientific reports·2020
Same author

Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV.

SAR and QSAR in environmental research·2020
Same author

Ultrasensitive Kilo-Pixel Imaging Array of Photon Noise-Limited Kinetic Inductance Detectors Over an Octave of Bandwidth for THz Astronomy.

Journal of low temperature physics·2019

Related Experiment Video

Updated: May 18, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Structure-activity relationship studies on clinically relevant HIV-1 NNRTIs.

R K Rawal1, V Murugesan, S B Katti

  • 1Medicinal and Process Chemistry Division, Central Drug Research Institute, Lucknow 226001, India.

Current Medicinal Chemistry
|September 25, 2012
PubMed
Summary

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are crucial for treating HIV-1. Structure-activity relationship studies explore novel NNRTIs, including 4-thiazolidinones, to overcome drug resistance and improve HIV therapy.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Related Experiment Videos

Last Updated: May 18, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Area of Science:

  • Medicinal Chemistry
  • Virology
  • Drug Discovery

Background:

  • Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a key class of drugs used in HIV-1 treatment, targeting the HIV-1 reverse transcriptase (RT) enzyme.
  • Approved NNRTIs include nevirapine, delavirdine, efavirenz, etravirine, and rilpivirine, which bind to an allosteric site on HIV-1 RT.
  • HIV-1 resistance to NNRTIs rapidly emerges due to mutations in the NNRTI-binding site.

Purpose of the Study:

  • To review recent advances in structure-activity relationship (SAR) studies of HIV-1 NNRTIs.
  • To discuss the development of novel NNRTI compounds, including those based on the 4-thiazolidinone scaffold.
  • To explore strategies for overcoming NNRTI resistance in HIV-1 treatment.

Main Methods:

  • Review of structure-activity relationship studies on established NNRTIs (nevirapine, delavirdine, efavirenz, etravirine, rilpivirine).
  • Investigation of novel NNRTI candidates, focusing on the 4-thiazolidinone scaffold.
  • Analysis of drug resistance mechanisms and strategies to circumvent them.

Main Results:

  • NNRTIs are effective when used alone or in combination with nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), leading to decreased viral load and increased CD4 T-cells.
  • SAR studies have identified key structural features influencing NNRTI efficacy and resistance profiles.
  • 4-thiazolidinones represent a promising privileged scaffold for developing new HIV-1 NNRTIs.

Conclusions:

  • Continued SAR studies are vital for developing next-generation NNRTIs to combat HIV-1 drug resistance.
  • Combination therapy involving NNRTIs remains a cornerstone of effective HIV-1 management.
  • Novel NNRTI scaffolds like 4-thiazolidinones offer potential for improved antiviral activity and resistance profiles.